MIRA Pharmaceuticals Sees Share Surge on Promising Data
MIRA Pharmaceuticals Stock on the Rise After Positive Developments
MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) has witnessed a notable increase in its stock value following the release of encouraging preclinical data regarding its flagship product, Ketamir-2. This advancement represents a significant step forward in the company's mission to revolutionize pain management.
Promising Preclinical Data for Ketamir-2
The exciting news stems from a presentation scheduled for the upcoming 18th Annual Pain Therapeutics Summit, where new findings related to Ketamir-2 will be shared. This novel oral Ketamine analog has demonstrated a remarkable 100% success rate in reversing neuropathic pain within preclinical models. This is a substantial achievement, especially in light of the challenges that neuropathic pain presents, often arising from nerve damage or dysfunction.
Ketamir-2's Mechanism and Benefits
Ketamir-2 distinguishes itself by selectively targeting the PCP site of the NMDA receptor, enhancing its therapeutic efficacy while minimizing side effects compared to traditional ketamine treatments. This unique approach opens up new avenues for effectively managing neuropathic pain, a condition that has long resisted adequate treatment solutions.
The Role of Dr. Itzchak Angel
At the Pain Therapeutics Summit, Dr. Itzchak Angel, the Chief Scientific Advisor of MIRA Pharmaceuticals, will present the data, shedding light on how Ketamir-2 can offer a path towards more effective pain management strategies. His expertise will provide valuable insights into the future of this promising drug and its potential impact on patients suffering from neuropathic pain.
Future Plans for Ketamir-2
MIRA Pharmaceuticals is dedicated to progressing the development of Ketamir-2, with plans to submit an Investigational New Drug (IND) application to the FDA by the end of 2024. The company is committed to demonstrating Ketamir-2's efficacy in human trials by 2025. Phase I/II studies are aimed at validating its effectiveness for treating not just neuropathic pain, but also other neurological conditions.
Current Stock Performance of MIRA
As the news of the favorable data spreads, MIRA shares closed up by an impressive 8.41%, reaching a price of $1.16 at the time of this report. This surge reflects investor confidence in the company's direction, particularly regarding Ketamir-2's future success once it enters the clinical trial phase.
Frequently Asked Questions
What is Ketamir-2 designed to treat?
Ketamir-2 is particularly focused on managing neuropathic pain and offers a novel approach to treatment compared to traditional ketamine therapies.
When will Ketamir-2 enter human trials?
The company aims to begin human trials by 2025, following the anticipated submission of its IND application to the FDA in late 2024.
Who is presenting the preclinical data at the summit?
Dr. Itzchak Angel, the Chief Scientific Advisor at MIRA Pharmaceuticals, will present the data at the 18th Annual Pain Therapeutics Summit.
How did MIRA shares respond to the news?
MIRA shares saw a rise of 8.41%, closing at $1.16, reflecting positive market sentiment regarding the new data.
What distinguishes Ketamir-2 from traditional treatments?
Ketamir-2 selectively targets the PCP site of the NMDA receptor, which may offer enhanced efficacy and fewer side effects than standard ketamine treatments.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- PulseSelect™ System Proves Effective in Real-World Ablation Cases
- Naveris Showcases Innovative Data on HPV Cancer Testing
- Metagenomi Inc. Shareholders: Important Class Action Update
- GitLab Investors Encouraged to Join Class Action Against Company
- City of New York Receives AA+ Long-Term Credit Rating
- China's Recent Stimulus Measures: A Key to Economic Revival
- Understanding the Sprinklr Securities Class Action Opportunity
- Key Insights into Lions Gate Entertainment Corp.'s Situation
- Investors Alert: CAE Inc. Securities Class Action Insights
- Moody's Downgrades Israel's Credit Rating Amid Rising Conflict
Recent Articles
- Understanding Cognizant Tech Solutions' P/E Ratio Strategy
- Unveiling the Investment Journey of Uber Technologies Stock
- Discovering Marvell Tech's Impressive Growth Over Five Years
- Armada Hoffler Prepares for Earnings Announcement This November
- Analyst Insights: Udemy Faces Tough Times Ahead with Changes
- VersaBank's Future Looks Bright with Analyst Upbeat on Growth
- PetMed Express Welcomes New Executives with Equity Awards
- CSX Pledges $100,000 for Hurricane Helene Relief Efforts
- Palantir's Inclusion in the S&P 500: Investment Implications
- Fannie Mae's Monthly Summary: Insights and Updates
- Indivior PLC Investors Can Lead Class Action for Securities Fraud
- Discover New Townhomes at Sunflower in Anaheim, CA
- Sigma Lithium's Strategy to Triple Capacity by 2026
- SIFCO Industries Welcomes Robert Johnson to Board of Directors
- Investors Unite for WEBTOON Entertainment Class Action Lawsuit
- Xcel Energy's Upcoming Earnings Call for Q3 2024 Insights
- Avangrid Increases Dividend to Enhance Shareholder Value
- How Keysight Technologies is Revolutionizing Connectivity Testing
- The New York Times Company Announces Dividend Declaration
- Uber's Food Delivery Growth: Analyst Predicts Over 25% Stock Upside
- SES AI's NYSE Compliance Efforts Following Listing Notice
- Frontline plc Shares Insights in Latest Half Year Report
- Pacific Coast Oil Trust Updates on Financial Status and Future
- Espey Mfg. & Electronics Corp. Posts Record Fiscal Year Results
- Chanson International Holding Reports Mixed Fiscal Results
- AllianceBernstein Reports Impressive Third Quarter Results
- Market Insights: Energy Stocks Surge as Dow Hits Record High
- Brazil's Electric and Hybrid Car Sales Set for a Major Surge
- Brookfield Property Partners Achieves New Growth Milestone
- flyExclusive Elevates Executives to Guide Growth Strategy
- NKGen Biotech's Path to Compliance Amid Market Challenges
- Horizon Space Acquisition Extends Merger Completion Timeline
- Sigma Lithium Plans to Triple Production by 2027 with Strategic Growth
- Transcode Therapeutics Navigates Nasdaq Compliance Challenges
- Recent FDA Updates: Key Approvals and Industry Changes
- Molecular Templates' Stockholder Meeting Highlights and Outlook
- Devon Energy Completes Significant Grayson Mill Acquisition
- VolitionRx Strengthens Leadership Amid Significant Growth
- Salarius Pharmaceuticals Announces Key 2024 Meeting Updates
- Ethiopia's Economic Reforms and IMF Loan Program Update
- Costco's Earnings Update: Is Now the Time to Invest?
- T-REX 2X Long MSTR ETF Poised for Exceptional Growth
- Energy Income Fund Offers Redemption Opportunity for Unitholders
- Citadel Income Fund Announces Opportunity for Unit Redemption
- Kirby Corporation Sets Dates for Upcoming Earnings Call and Release
- Orange Initiates Share Buyback Program for Long-Term Incentives
- Gateway Fiber Launches High-Speed Internet with Local Focus
- Frontline plc Releases Half Yearly Report Highlighting Growth
- Clover Leaf Capital Corp. Holds Special Meeting to Discuss Future
- flyExclusive Strengthens Leadership Team with Key Roles